clinical study News
-
Clinical Studies
Through the years we have heard from many T-Stat users that they would like to collect their case data, review and present their findings. The transferring of data was limited to physically doing this on the T-Stat with a thumb drive. Now we have a new feature that is built into our remote access web application OnCall. If you want to collect your data you can easily request this in ...
-
New Clinical Study
Gelmetix is happy to announce a clinical study has been approved by the French Medical Authorities to investigate the benefit of the injection of the DXM gel to help alleviating pain from Chronic Lower Back pain patients. Pr Jean Charles Le Huec, from Bordeaux, France will drive the study as Principal Investigator. Information can be obtained at Polyclinique Bordeaux Nord in France. ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients
ImCare Biotech completes a prospective, blinded clinical study with over 500 patients in order to evaluate the use of their novel biomarker, Seravue®, for the purposes of detecting Hepatocellular Carcinoma in its early and later stages. ...
-
Balanseat by Mopair is exited to become a partner of FAITH
Within FAITH, a large number of parties are pooling their expertise and experiences in the field of frailty. Together FAITH provides more insight, practice-oriented knowledge, evidence-based interventions and conducts research into application in a personalized approach with an eye for the possibilities of technology and eHealth. Under FAITH umbrella, Balanseat is initiating a clinical study on ...
By Balanseat
-
PhysioAssist and the French CF patient association sign a partnership
PhysioAssist and the French CF patient association ‘Vaincre La Mucoviscidose’ have just signed a partnership to facilitate access to the use of the Simeox device at home. We are delighted about this partnership with the association Vaincre La Mucoviscidose, for allowing an easy access without engagement, as well as financial assistance by the association to the patients who wish to ...
By PhysioAssist
-
Cytex Showcases to NIH Investor Forum
Cytex was pleased to participate in the Life Sciences Showcase Conference, hosted virtually by the National Institutes of Health. This Conference, held in November 2020, is a leading forum for early stage innovators to present their companies to potential partners and investors. Cytex President and COO Bradley Estes, PhD., gave a virtual presentation on the current stage of Cytex implant ...
-
4Q 2021 Stakeholder Update
Progress Update December 27th, 2021 Year End Summary 2021 was a great year of progress for Second Heart Assist, Inc. We completed a large series of large animals with long duration use at Texas Heart Institute with great success. We believe we are set now to begin a cardio-renal syndrome clinical study with 24 hours circulatory assist support time in 1Q 2022. Our team believes we are in the ...
-
Ablacon Announces Release of New and Improved Ablamap Technology Under Existing CE Mark
Ablacon, Inc. (www.ablacon.com), an Ajax Health-funded company, announced today the release of an updated version of its Ablamap technology under the company’s existing CE Mark. The new update includes an enhanced physician experience and user interface, along with significantly faster processing times leading to improved procedural efficiency. It will be rolled out to all current centers ...
-
We are looking for a Clinical Project Manager
Join us when we are expanding our unit with another Clinical Project Manager. In this role, you will lead the planning, execution and documentation of clinical studies for our late clinical phase vaccine products. Join us in our work to give people worldwide a longer and better life. We are an entrepreneurial company and experts in global vaccine development, manufacturing, registration and ...
-
Vektor Medical Initiates Clinical Study of vMap
Vektor Medical, Inc. announced the start of its clinical study to evaluate vMap™. Using patients who have previously undergone a clinically-indicated electrophysiology study and successful ablation, the purpose of this study is to clinically validate the use of vMap™ in providing arrhythmia/pacing hotspots for analysis by a physician. vMap™ has been designed as the next ...
-
ACOA Anounces $3M in Support to ABK for Easi-Vue Embolization Microspheres
ABK Biomedical received support from the Atlantic Canada Opportunities Agency (ACOA) to commercialize its Easi-Vue embolization microspheres in-house. The successful commercialization of this innovation will lead to new business opportunities and more well-paying jobs as the microspheres are set to compete in global markets. The funding was announced in February 2018 at ABK’s new facility ...
-
Canaquest - Recent developments
Pharmaceutical: We are perfecting our CQ-001 Drug Candidate (CBD based IP formula) delivery system for Epilepsy in readiness for another Clinical Study for efficacy at the Ontario Brain Institute “OBI”……targeting September. Our first Clinical Study at OBI already achieved a 20% reduction in seizures……..we believe we can do better with our more concentrated ...
-
Sutro Biopharma to Present at the 2022 Wells Fargo Healthcare Conference
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wells Fargo Healthcare Conference on Friday, September 9, 2022, at 10:25 a.m. ET / 7:25 a.m. PT in Boston. The presentation will be accessible ...
-
Fusion Genomics Receives $1 Million from CQDM To Study ONETest RTI Assay
We are pleased to share the news that Fusion Genomics has received a $1 million award to conduct a study evaluating our comprehensive, novel ONETest PathoGenome assay for the detection of pathogens associated with respiratory tract infections (RTIs). Due in great part to limitations associated with current diagnostic tests, RTIs are a leading cause of morbidity, mortality, and hospitalizations ...
-
NeoTherma Oncology Opens Clinical Study - Wichita, Kansas
NeoTherma Oncology, having achieved both FDA approval for its Investigational Device Exemption for an Early Feasibility Study of the VectRx™ System and institutional review board approval at an east coast National Cancer Institute-designated Cancer Center, has initiated recruitment for a first-in-human trial in patients with pancreatic ...
-
Sutro Biopharma to Present at the 2022 Wedbush PacGrow Healthcare Conference
Sutro Biopharma, Inc. (Sutro or the Company) (NASDAQ: STRO), a clinical-stage oncology company pioneering site-specific and novel-format antibody drug conjugates (ADCs), today announced that Bill Newell, Chief Executive Officer, will present at the 2022 Wedbush PacGrow Healthcare Conference’s panel discussion, “ADCs – Take Me to Your Tumor” on Wednesday, August 10, 2022, ...
-
Starton Therapeutics Provides Update on STAR-LLD Lenalidomide Clinical Program
Starton Therapeutics Inc., a clinical stage biotechnology company provides updates on its first-in-human Phase 1 STAR-LLD clinical trial of its investigational continuous delivery lenalidomide, in healthy subjects. Four subjects in the first cohort received 24 hours of STAR-LLD continuous lenalidomide, and a single oral dose of lenalidomide after a 24 hour washout period. The Independent Data ...
-
Healx receives IND and Orphan Drug Designation for fragile X clinical trial
Healx has received Investigational New Drug (IND) approval from the US Food and Drug Administration (FDA) for the Phase 2a clinical study of the compound HLX-0201 for Fragile X syndrome. The clinical study will attempt to find at least one novel and effective combination therapy for Fragile X syndrome - the world’s leading inherited cause of autism and learning difficulties which affects ...
By Healx Ltd.
-
Adagio Medical Announces US FDA Investigational Device Exemption Approval With Conditions to Conduct A Clinical Study for Treatment of Persistent Atrial Fibrillation Using The Ultra-Low Temperature Cryoablation System
Adagio Medical, Inc. (Adagio), the developer of iCLAS™, the company’s ultra-low temperature intelligent continuous lesion ablation system, announced that it has received an Investigational Device Exemption approval with conditions from the US Food and Drug Administration (FDA) to conduct a non-randomized, single-arm clinical study for persistent atrial fibrillation (AF). The study ...
Need help finding the right suppliers? Try XPRT Sourcing. Let the XPRTs do the work for you